Voyageur Pharmaceuticals Ltd. Share Price OTC Markets
Stocks
VYYRF
CA92918C1014
Pharmaceuticals
OTC Markets Traded|
Market Closed -
OTC Markets
15:31:17 19/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.1200 USD | 0.00% |
|
0.00% | -7.76% |
| Market Cap | 35.08M 25.48M 21.83M 20.42M 18.69M 2.44B 35.55M 241M 94.09M 1.22B 95.67M 93.59M 4.05B | P/E 2024 |
-5.24x | P/E 2025 | -7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 34.85M 25.31M 21.68M 20.29M 18.57M 2.42B 35.31M 240M 93.47M 1.22B 95.04M 92.98M 4.02B | EV / Sales 2024 |
-
| EV / Sales 2025 | 2,423,581,172x |
| Free-Float |
93.07% | Yield 2024 * |
-
| Yield 2025 | - |
| Current month | +25.00% | ||
| 1 month | +9.09% | ||
| 3 months | +99.34% | ||
| 6 months | +9.09% | ||
| Current year | -7.76% |
| 1 week | 0.12 | 0.12 | |
| 1 month | 0.1 | 0.13 | |
| Current year | 0.01 | 0.2 | |
| 1 year | 0 | 0.2 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.25 | |
| 10 years | 0 | 0.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brent Willis
CEO | Chief Executive Officer | - | 30/06/2019 |
| Director of Finance/CFO | - | 16/08/2022 | |
Iryna Saranchova
CTO | Chief Tech/Sci/R&D Officer | - | 16/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Brent Willis
BRD | Director/Board Member | - | 05/12/2017 |
Brad Willis
BRD | Director/Board Member | - | 30/06/2019 |
Eric Pommer
CHM | Chairman | - | 29/04/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | - | - | 25.48M | ||
| +0.88% | +6.38% | +76.86% | +128.23% | 1,119B | ||
| +1.07% | +3.80% | +51.03% | +61.48% | 651B | ||
| +1.20% | +6.21% | +26.47% | +76.45% | 468B | ||
| +1.02% | +5.77% | +43.09% | +47.70% | 374B | ||
| +0.85% | +4.07% | +23.88% | +41.58% | 302B | ||
| +1.26% | +6.81% | +1.59% | +14.67% | 259B | ||
| +1.88% | +5.81% | +48.54% | +68.52% | 238B | ||
| +1.59% | +2.09% | -15.52% | -52.29% | 208B | ||
| +1.87% | +5.61% | +25.81% | +92.42% | 181B | ||
| Average | +1.16% | +4.97% | +31.31% | +53.20% | 422.21B | |
| Weighted average by Cap. | +1.14% | +5.09% | +44.31% | +72.55% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 0.01 0.01 0.01 0.01 0.01 0.81 0.01 0.08 0.03 0.41 0.03 0.03 1.35 |
| Net income | -1.71M -1.24M -1.06M -994K -910K -119M -1.73M -11.74M -4.58M -59.6M -4.66M -4.55M -197M | -3.53M -2.57M -2.2M -2.06M -1.88M -245M -3.58M -24.29M -9.47M -123M -9.63M -9.42M -408M |
| Net Debt | -113K -81.8K -70.07K -65.56K -60.02K -7.83M -114K -775K -302K -3.93M -307K -300K -13M | -231K -167K -143K -134K -123K -16.02M -234K -1.59M -618K -8.05M -629K -615K -26.62M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/08/26 | US$0.1200 | 0.00% | 100,000 |
| 17/08/26 | US$0.1200 | 0.00% | 70,500 |
| 14/08/26 | US$0.1200 | 0.00% | 17,000 |
| 13/08/26 | US$0.1200 | 0.00% | 14,000 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VM Stock
- VYYRF Stock
Select your edition
All financial news and data tailored to specific country editions
















